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Summary and Implications 
Ninety, 12-14 day old pigs were randomly assigned 
to five groups. Group 1 (n=19) pigs were vaccinated with 
a Mycoplasma hyopneumoniae (M. hyopneumoniae) 
vaccine with an oil-in-water adjuvant (RespiSure®; Pfizer 
Animal Health, Inc.). Group 2 (n=17) pigs were 
vaccinated with a commercial M. hyopneumoniae vaccine 
with an aqueous adjuvant (Carbopol) (Suvaxyn® 
Respifend® MH; Fort Dodge Animal Health, Inc.). Group 
3 (n=18) pigs were vaccinated using an oil-in-water 
adjuvanted vaccine containing the same amount and type 
of M. hyopneumoniae antigen as in group 2. Group 4 
(n=18) pigs were vaccinated using an aluminum 
hydroxide adjuvanted vaccine containing the same 
amount and type of M. hyopneumoniae antigen as in 
group 2. Group 5 (n=18) pigs served as the controls and 
were sham-vaccinated with saline. Pigs were injected with 
2 mL of one of the four M. hyopneumoniae vaccines at 
four and again at six weeks of age. PCV2 was inoculated 
intranasally on the day of the second vaccination at 6 
weeks of age. Half of the pigs were necropsied at 21 days 
post inoculation (DPI). The remaining pigs were 
necropsied at 35 DPI. 
There were no differences among groups in clinical 
disease scores. At 21 DPI all vaccinated groups had 
significantly (p<0.05) more severe lymphoid depletion 
than the saline injected group. At 35 DPI group 1 pigs had 
significantly (p<0.05) higher amounts of PCV2 DNA in 
serum than pigs in groups 2, 4, and 5 as determined by 
quantitative real-time PCR. There was a significant 
(p<0.05) increase in the severity of lymphoid depletion in 
the lymph nodes, tonsil, and spleen in groups 1 and 3 
compared to groups 2, 4, and 5. Group 3 had significantly 
(p<0.05) higher amounts of PCV2 antigen within lymph 
nodes, tonsil, and spleen compared to groups 2, 4 and 5. 
The results confirm that all adjuvants tested enhanced 
PCV2-induced lesions and oil-in-water products used in 
this study had a more severe effect. 
 
Introduction 
PCV2 is associated with postweaning multisystemic 
wasting syndrome (PMWS) and has quickly become a 
major global problem in the swine industry. Recent 
experiments in Europe and by our group in the U.S. have 
confirmed that vaccination of pigs with commercially 
available M. hyopneumoniae bacterins significantly 
increases the length of PCV2 viremia, the amount of 
PCV2 in serum and lymphoid tissues, and the severity of 
PCV2-associated lymphoid depletion.  
The objectives of this study were to determine if 
commercially available adjuvants (as opposed to the 
antigen) enhance PCV2-associated lesions and if there is a 
difference among adjuvants in this enhancement. If 
differences are present producers may need to consider 
this in vaccine selection. 
 
Materials and Methods 
Ninety, 12-14 days old pigs were randomly assigned 
to five groups of 17-19 pigs each. Groups 1-4 pigs were 
vaccinated with 2 mL of one of four M. hyopneumoniae 
bacterins at four and again at six weeks of age (Table 1). 
To exclude a potential effect of the M. hyopneumoniae 
antigen, three of the vaccines (groups 2-4) used in this 
model contained the same type and amount of M. 
hyopneumoniae antigen and varied only in the kind of 
adjuvant used.  
 
Table 1: Experimental design 
Group Adjuvant type Mycoplasma antigen 
1 Oil-in-water type 1 Type A 
2 Carbopol Type B 
3 Oil-in-water type 2 Type B 
4 Aluminum hydroxide Type B 
5 Control (Saline) Control (Saline) 
 
Vaccines used in group 1 (RespiSure®, Pfizer 
Animal Health) and group 2 (Suvaxyn® Respifend® MH, 
Fort Dodge Animal Health) are commercially available. 
The vaccines in groups 3 and 4 are experimental. All pigs 
were inoculated intranasally with PCV2 isolate ISU-
40895 on the day of the second vaccination at 6 weeks of 
age.  
Blood was collected weekly and analyzed for the 
presence of PCV2-specific antibodies by an ELISA and to 
assess the amount of PCV2 by quantitative real-time PCR. 
Necropsies were performed on half of the pigs at 21 and 
half at 35 DPI. Selected tissue samples (lung, lymph 
nodes, spleen, liver, kidney, tonsil, heart) were placed in 
10% neutral buffered formalin and routinely processed for 
histopathological examination. Immunohistochemistry 
(IHC) for PCV2 was done on paraffin embedded sections 
of lymph nodes, spleen and tonsil. 
Analysis of variance (ANOVA) was used to check for 
differences among groups. If the ANOVA was signficant 
(p<0.05) pairwise Wilcoxon tests were performed to 
identify the groups that were different. 
 
Results and Discussion 
Clinical scores and average daily weight gain were 
similar among groups. Significant differences among 
groups were not evident for severity of gross lesions.  All 
vaccinated groups had significantly (p<0.05) more severe 
lymphoid depletion than the controls at 21 DPI.  
At 35 DPI, there was significantly (p<0.05) more 
severe lymphoid depletion and granulomatous 
inflammation in the lymph nodes, spleen, and tonsil in 
group 1 compared to groups 2 and 4. Group 3 had 
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significantly (p<0.05) higher amounts of PCV2 antigen in 
lymph nodes, tonsil, and spleen compared to group 2 and 
4. At 35 DPI, group 1 pigs had significantly (p<0.05) 
higher amounts of PCV2 DNA in serum than pigs in 
groups 2, 4, and 5. 
This work suggests that at the early stages of PCV2 
infection (21 DPI), all the adjuvants tested (oil-in-water, 
carbopol, aluminum hydroxide) increased the severity of 
lymphoid depletion associated with PCV2. In the later 
stages of infection (35 DPI), the oil-in-water adjuvants 
increased the severity of PCV2-associated lesions, 
viremia length, and amount of PCV2 in serum and tissue 
compared to carbopol and aluminum hydroxide products. 
Producers with recurrent PCV2-associated disease 
may want to consider switching to the carbopol or 
aluminum-hydroxide adjuvanted products, discontinuing 
use of vaccines on PCV2-infected pigs, or changing the 
timing of vaccine administration. However, producers and 
practitioners must always consider the risk and benefit 
from elimination of vaccination and decrease control of 
coinfection 
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